

Press release – For immediate release September 6, 2024 – 5:45 pm CEST

Disclosure of total number of voting rights and number of shares in the capital as of August 31st, 2024

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.

Sophia Antipolis, France

Total number of shares	18,448,233
Number of real voting rights* (excluding treasury shares**)	18,363,983
Theoretical number of voting rights* (including treasury shares**)	18,425,033

(*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations



About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on

the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

Contacts

Median Technologies	Press - ALIZE RP	Investors - ACTIFIN
Emmanuelle Leygues	Caroline Carmagnol	Ghislaine Gasparetto
Head of Corporate Marketing & Financial	+33 6 64 18 99 59	+33 6 21 10 49 24
Communications	median@alizerp.com	ghislaine.gasparetto@seitosei-actifin.com
+33 6 10 93 58 88		
emmanuelle.leygues@mediantechnologies.com		